Study found 99% of vaccinated people in Serrana seroconverted.The indicator was higher than the results from the clinical trials from phases one and two of CoronaVac, showing seroconversion at around 97 and 98 percent, respectively, depending on the dose.
ButanVac will be produced at the Butantan factory where flu vaccines are made—a production that has already come to an end this year. ButanVac will be fully manufactured in São Paulo, with no imported supplies necessary.
They are variant B.1.318, found in Switzerland and the UK; South African B.1.351; and N9, a mutation of Amazon variant P1, observed in a number of Brazilian states.
It is efficient against the British B.1.1.7, the South African B.1.351, and Brazil’s B.1.1.28, of which are derived variants P.1, from Manaus, and P.2, from Rio de Janeiro.